Overview

Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Treatments:
Aspirin
Protective Agents